This CME activity examines the science of atherosclerotic disease development and discusses the cost-effective benefits of primary and secondary prevention of atherosclerotic disease.
Expiration Date: January 31, 2011
Intended for “managed care medical directors, pharmacy directors, and other physicians and pharmacists interested in the management of atherosclerosis,” this online CME activity is a “synthesis of material presented in a series of audioconferences” that also incorporates dialogue from the original roundtable discussions.
This publication was prepared by Paul M Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at Harvard Medical School and director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital in Boston, and Harry L. Leider, MD, MBA, Chief Medical Officer and Sr. VP at Ameritox, Ltd., and Senior Fellow in the Department of Health Policy & Outcomes at Thomas Jefferson University.
The 20-page monograph that presents the core content of this CME activity “examines the science of atherosclerotic disease development, exploring the role of inflammation in its pathogenesis,” and discusses the cost effective benefits of primary and secondary prevention of atherosclerotic disease.
Physicians who complete this activity will have a better understanding of recent developments in the evolving concept of the biology of atherosclerosis and atherothrombosis, the healthcare burden of atherosclerosis and the financial value to payors that could be realized by focusing on primary as well as secondary prevention, and methods for enhancing physician and patient adherence to evidence-based guidelines and treatment.
Click here to access this third-party CME activity.